Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Author Disclosure Information PowerPoint Presentation
Download Presentation
Author Disclosure Information

Author Disclosure Information

122 Vues Download Presentation
Télécharger la présentation

Author Disclosure Information

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission BV301Phase III clinical trial results Schuster SJ*, Neelapu SS*, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, Winter JN, Flowers CR, Stergiou AM, Kwak LW on behalf of the BV301 Phase III Study Investigators

  2. Author Disclosure Information

  3. Non-Hodgkin Lymphomas (NHL) • 6th most common type of cancer in the US 1 • Most common hematological cancer • 65,980 new cases expected in the US in 2009 2 • 19,500 are expected to die of NHL in 2009 2 • Follicular lymphoma is the second most common subtype of NHL, accounting for ~25% of all NHL diagnoses 3 1 http://www.cancer.gov/cancertopics/commoncancers#1 2 American Cancer Society. Cancer Facts & Figures 2009. 3 Blood 89: 3909, 1997

  4. Follicular Lymphoma • B-cell immunophenotype • Clonal surface immunoglobulin (tumor-specific idiotype) • Median survival ranges from 5 to >10 years depending on prognostic factors 1 • Disease-free and overall survival are improved by combining rituximab with chemotherapy 2,3 • No curative therapy for most patients 1 Solal-Celigny, et al. Blood 104:1258, 2004 2 Marcus, et al. J Clin Oncol 26:4579, 2008 3 Hochster, et al. J Clin Oncol 27:1607, 2009

  5. Id+KLH Protein (BiovaxID) • The idiotype of the SmIg of a B-cell lymphoma canbe used as a tumor-specific immunogen that induces immunity against Id-bearing tumor cells • Keyhole lympet hemocyanin (KLH) carrier serves as an immune stimulant • GM-CSF administered concurrently at site of injection as an adjuvant antigen binding site / idiotype KLH (with GM-CSF)

  6. Idiotype Vaccine Production tumor cell myeloma cell LN biopsy + fusion I heterohybridoma KLHconjugation Id scale-up affinity purification

  7. Id-KLH (BiovaxID) Pre-Clinical and Clinical Trials Start of Phase IIClinical Trial (1993) Biovest TransferIND from NCI (2004)

  8. NCI Phase II Follicular Lymphoma Idiotype Vaccine Study Results • N=20 in CR > 6 months after PACE received • Id-KLH + GM-CSF vaccination • At median follow-up of 9.2 yrs, 45% (9 / 20 pts) in CR; overall survival 95% • Anti-Id antibody response (15 / 20 pts) • Tumor-Specific CD4+ and CD8+ T-cell responses(19 / 20 pts) * • Conversion to t(14;18) PCR-negative (8 / 11 pts) † *HLA class I restriction of cytokine release and cytotoxicity are suggestive of cytotoxic CD8+ T-cell response. †Molecular remission sustained for >18 mo. Bendandi et al. Nat Med 5:1171, 1999Santos et al. Blood (ASH Abstract #2441), 2005.

  9. BV301 Phase III Follicular Lymphoma Idiotype Vaccine Study Objectives • Primary Objective: • To determine whether Id-KLH (BiovaxID) + GM-CSF prolongs disease free survival (DFS) compared to KLH + GM-CSF (control vaccine) in patients with follicular lymphoma in CR/CRu after PACE • Secondary Objectives: • Evaluate safety of Id-KLH (BiovaxID) + GM-CSF • Compare overall survival of subjects in both treatment arms • Evaluate immunologic and molecular responses

  10. BV301 Phase III Follicular Lymphoma Idiotype Vaccine Study Design Id-KLH + GM-CSF PACE Chemo Stratify for IPI1, cycles of PACE2 2:1 Randomization LN Bx KLH + GM-CSF Assign CR Timeline 6 - 12 months 6 months 6 - 8 months • Primary endpoint: disease-free survival • 14 sites enrolled patients from 2000-2007 1low, low-intermediate or high-intermediate, high groups 2 < 8 or > 8 cycles

  11. Inclusion Criteria • Follicular lymphoma with monoclonal surface IgM or IgG • Follicular lymphoma histology, grades 1, 2, or 3a • Stage III or IV lymphoma (including Stage IIX ) • Chemotherapy naïve •  2 sites previous radiation treatment • > 2cm single lymph node accessible for biopsy

  12. Induction Chemotherapy (PACE)

  13. Statistical Design: Sample Size • Assumed 2/3 CR/CRu response to PACE • required 563 pts for 2:1 randomization of 375 pts to either Id-KLH (BiovaxID) arm (250) or control arm (125) • 80% power to detect a difference between DFS curves with an initial hazard ratio of 1.0 and an intended hazard ratio of 0.5 after the first 8 months

  14. Statistical Design: Two Prospective Efficacy Analyses • Intent-to-Treat Analysis (ITT) compared DFS in treatment arms for all randomized pts • Modified Intent-to-Treat Analysis (mITT) compared DFS in treatment arms for randomized pts who remained in CR/CRu and received either Id-KLH (BiovaxID) or control

  15. Study Concluded Based on DMC Recommendation • Recommendation of DMC: • Review of trial objectives and results • Impact on accrual related to change in standard of care to include rituximab • No safety concerns for Id-KLH (BiovaxID) • Independent Data Monitoring Committee (DMC) • G. Messerschmidt, M.D. (Chairman) • Prof. V. Diehl, M.D., Ph.D. (Member) • H. Parise, Sc.D. (Member, Statistician)

  16. Results Enrollment Stratify / Randomize ITT (n=177) Post-InductionRecoveryPeriod(6-12 months) PD, no vax (n=60) modified ITT (n=117) Vaccination

  17. Results: DFS for All Randomized Patients(ITT) • For all randomized pts, no statistically significant difference in DFS was observed between pts allocated to Id-KLH (BiovaxID) or control arms. • The intent of the protocol was to compare DFS in pts vaccinated in CR/CRu with either Id-KLH or control vaccine. • The ITT analysis compares DFS in all randomized pts, including pts not vaccinated.

  18. Characteristics of Patients Relapsing After Randomization and Before Vaccination (n=60) No statistically significant (p < 0.05) differences between the two arms for any patient characteristics

  19. DFS for Patients Relapsing After Randomization and Before Vaccination (n = 60) Id-KLH (BiovaxID) arm control vaccine arm Probability Months from Randomization

  20. Characteristics of Patients Receiving Id-KLH (BiovaxID) vs. Control Vaccine (mITT, n=117) No statistically significant (p < 0.05) differences between the two arms for any patient characteristics

  21. Overall Survival from Randomization for Id-KLH (BiovaxID) vs. Control Arms (mITT) • Median OS • not yet reached at median follow-up 56.6 months • Overall Survival • Id-KLH (BiovaxID) = 95.4% • Control vaccine = 91.2% • N = 117 • Id-KLH (BiovaxID) N = 76 • Control vaccine N = 41 • Events • Id-KLH (BiovaxID) = 3 • Control vaccine = 2 • Cox PH Model • HR = 0.7 (p=0.7) Id-KLH (BiovaxID) arm control vaccine arm

  22. Disease Free Survival from Randomization for Id-KLH (BiovaxID) vs. Control Arms (mITT) • Median Follow-up • 56.6 mo (range 12.6 – 89.3) • Median DFS • Id-KLH (BiovaxID) = 44.2 mo • Control vaccine = 30.6 mo • N = 117 • Id-KLH (BiovaxID) N = 76 • Control vaccine N = 41 • Events • Id-KLH (BiovaxID) = 44 • Control vaccine = 29 • Cox PH Model • HR = 0.62; [95% CI: 0.39,0.99] (p=0.047) Id-KLH (BiovaxID) arm control vaccine arm log-rank p=0.045

  23. Safety Summary: AEs During Vaccination CTCAE Version 2

  24. Results: Local Injection Site Reactions

  25. Conclusions • Id-KLH (BiovaxID) + GM-CSF vaccination improves DFS following PACE in patients in CR/CRu at time of vaccination • CR/CRu could be a prerequisite for achieving benefit from vaccination • Long-term clinical experience with idiotype vaccination demonstrates low toxicity profile • Tumor-specific idiotype vaccine can be successfully manufactured using heterohybridoma and bioreactor technologies

  26. Future Plans • Complete immune response testing on samples collected during the clinical trial • Study Id-KLH (BiovaxID) following rituximab-combination chemotherapy regimens • Study Id-KLH booster vaccination schedules • Sponsor will continue regulatory approval discussions with US and EU regulatory agencies

  27. BV301 Trial Sites • National Cancer Institute • Duke University Medical Center • Emory University Winship Cancer Institute • H. Lee Moffitt Cancer Center • New England Medical Center • New York University Medical Center • Virginia Oncology Associates • North Mississippi Hem & Oncology Associates • Northwestern University • St. Mary's/Duluth Clinic (SMDC) Health System • Abramson Cancer Center University of Pennsylvania • The University Of Texas MD Anderson Cancer Center • Westchester Oncology & Hematology Group • Southern Oncology Research